From Nasdaq:

CRISPR Therapeutics AG closed at $70.01, a +1.71% increase. Shares gained 6.15% over the past month, outpacing the Medical sector’s 2.05% and the S&P 500’s 5.07%. Anticipated earnings per share is -$0.21, an 85.11% rise; projected revenue is $144.28 million, a 1442670% rise.

CRISPR Therapeutics AG analyst estimates point to positive business and profitability shifts. Estimate changes directly impact stock price. The Zacks Rank model system reflects an actionable rating system with annual gains of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.06% higher over the past month.

With a Zacks Rank of #3 (Hold), CRISPR Therapeutics AG is part of the Medical – Biomedical and Genetics industry. There’s a Zacks Industry Rank of 103, placing it in the top 41% of all 250+ industries. The top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Watch for key stock-moving metrics using Zacks.com as well as the “Single Best Pick to Double”. The industry’s best potential stocks are scientifically selected by experts. The currently identified company is a little-known chemical company with huge upside potential rivaling recent Zacks’ Stocks Set to Double performances.

If you want to read this article on Zacks.com click here.



Read more: CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here’s Why